WEBThe innovation behind a breakthrough. Our company is committed to developing novel, safe, and efficacious therapies to improve the lives of people with rare diseases.
DA:96PA:34MOZ Rank:4
Catalyst Pharmaceuticals, Inc. (CPRX) - Yahoo Finance
WEBCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and...
DA:38PA:18MOZ Rank:36
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full …
WEBFeb 28, 2024 · Catalyst Pharmaceuticals, Inc. Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022. Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an ...
WEBMar 12, 2024 · Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases.
WEBCatalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida. The company is developing medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS).
DA:19PA:78MOZ Rank:90
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® …
WEBCORAL GABLES, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today reported that Santhera Pharmaceuticals ("Santhera") has obtained U.S. Food and Drug Administration ("FDA") approval for AGAMREE ® (vamorolone) oral suspension 40 mg/mL for use in treating …
WEBCatalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. Our mission To improve the lives of patients with rare and ultra-rare diseases
WEBFeb 14, 2024 · CORAL GABLES, Fla. , Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and
DA:44PA:7MOZ Rank:100
Catalyst Pharmaceuticals Announces FDA Acceptance of the
WEBOct 13, 2023 · U.S. FDA Assigned Target Action Date of June 4, 2024. CORAL GABLES, Fla., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced ...
DA:73PA:11MOZ Rank:75
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 …
WEBNov 9, 2022 · Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update. November 9, 2022 at 4:11 PM EST. Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase. Company Increases Full Year 2022 Total Revenue Guidance to $205-210 Million.